Alberta Stroke Program Early News Today

Prof. Dorn discusses findings and potential future impacts of the TENSION trial and German Stroke Registry, thoughts on female representation and prioritizing families in the interventional neuroradiology profession, improvements needed in stroke protocol...

SELECT2 trial's 1-year results show continued benefits for patients with slower recovery

The findings suggest these types of patients continue to improve beyond 3-6 months and thus might benefit from longer rehab.

With recent advances in endovascular devices and techniques for the treatment of large-vessel occlusion (LVO) stroke, rates of successful recanalization are as

This clinical trial assesses the efficacy and adverse events of adjunctive intravenous low-dose methylprednisolone to endovascular thrombectomy for patients wit

This individual participant data meta-analysis assesses treatment time from stroke symptom onset and disability level after treatment with intravenous thromboly

This exploratory analysis of the SELECT2 trial assesses the relationship between imaging estimates of irreversibly injured brain (core) and at-risk regions (mis

Nearly 1 in 3 patients who underwent stroke thrombolysis in this study had stage 3 or higher chronic kidney disease. Kidney dysfunction appears to be a crucial determinant of death risk among patients with stroke thrombolysis.

In patients with acute ischemic stroke, lower SBP targets following successful endovascular therapy do not meet criteria for futility.

In patients with acute ischemic stroke, lower SBP targets following successful endovascular therapy do not usually meet prespecified criteria for futility.